Albert Lowe
Stock Analyst at Craig-Hallum
(1.57)
# 3,466
Out of 5,090 analysts
10
Total ratings
22.22%
Success rate
5.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Initiates: Buy | $175 | $100.49 | +74.15% | 1 | Dec 4, 2025 | |
| NGNE Neurogene | Initiates: Buy | $50 | $20.28 | +146.55% | 1 | Jun 17, 2025 | |
| ATOS Atossa Therapeutics | Initiates: Buy | $4 | $0.80 | +400.44% | 1 | Jun 5, 2025 | |
| IRD Opus Genetics | Initiates: Buy | $6 | $2.27 | +164.32% | 1 | Apr 11, 2025 | |
| SKYE Skye Bioscience | Maintains: Buy | $18 → $14 | $1.20 | +1,066.67% | 2 | Mar 21, 2025 | |
| SABS SAB Biotherapeutics | Initiates: Buy | $11 | $3.98 | +176.38% | 1 | Oct 9, 2024 | |
| CRDF Cardiff Oncology | Initiates: Buy | $8 | $2.11 | +279.15% | 1 | Sep 6, 2024 | |
| LCTX Lineage Cell Therapeutics | Initiates: Buy | $4 | $1.72 | +132.56% | 1 | Aug 20, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $6 | $1.19 | +404.20% | 1 | May 13, 2024 |
Palvella Therapeutics
Dec 4, 2025
Initiates: Buy
Price Target: $175
Current: $100.49
Upside: +74.15%
Neurogene
Jun 17, 2025
Initiates: Buy
Price Target: $50
Current: $20.28
Upside: +146.55%
Atossa Therapeutics
Jun 5, 2025
Initiates: Buy
Price Target: $4
Current: $0.80
Upside: +400.44%
Opus Genetics
Apr 11, 2025
Initiates: Buy
Price Target: $6
Current: $2.27
Upside: +164.32%
Skye Bioscience
Mar 21, 2025
Maintains: Buy
Price Target: $18 → $14
Current: $1.20
Upside: +1,066.67%
SAB Biotherapeutics
Oct 9, 2024
Initiates: Buy
Price Target: $11
Current: $3.98
Upside: +176.38%
Cardiff Oncology
Sep 6, 2024
Initiates: Buy
Price Target: $8
Current: $2.11
Upside: +279.15%
Lineage Cell Therapeutics
Aug 20, 2024
Initiates: Buy
Price Target: $4
Current: $1.72
Upside: +132.56%
PMV Pharmaceuticals
May 13, 2024
Initiates: Buy
Price Target: $6
Current: $1.19
Upside: +404.20%